Literature DB >> 9671342

Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study.

F R Levin1, S M Evans, D M McDowell, H D Kleber.   

Abstract

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is common among cocaine abusers seeking treatment. This open trial was carried out to assess the efficacy of sustained-release methylphenidate for the treatment of cocaine abuse among individuals with ADHD.
METHOD: Twelve patients who met DSM-IV diagnostic criteria for adult ADHD and cocaine dependence were entered into a 12-week trial of divided daily doses of sustained-release methylphenidate ranging from 40 to 80 mg. In addition to the pharmacotherapy, patients also received individual weekly relapse prevention therapy. Individuals were assessed weekly for ADHD symptoms; vital signs and urine toxicologies were obtained 3 times a week.
RESULTS: Of the 12 patients entered, 10 completed at least 8 weeks of the study and 8 completed the entire study. Using both a semistructured clinical interview and a self-report assessment, patients reported reductions in attention difficulties, hyperactivity, and impulsivity. Self-reported cocaine use and craving decreased significantly. More importantly, cocaine use, confirmed by urine toxicologies, also decreased significantly.
CONCLUSION: These preliminary data suggest that under close supervision, the combined intervention of sustained-release methylphenidate and relapse prevention therapy may be effective in treating individuals with both adult ADHD and cocaine dependence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671342     DOI: 10.4088/jcp.v59n0605

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  24 in total

Review 1.  Current concepts in pharmacotherapy of substance abuse.

Authors:  P C Gottschalk; L K Jacobsen; T R Kosten
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

Review 2.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

3.  Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Xavier Castells; Lídia Blanco-Silvente; Ruth Cunill
Journal:  Cochrane Database Syst Rev       Date:  2018-08-09

4.  Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys.

Authors:  Charles W Schindler; Joanne P Gilman; Leigh V Panlilio; David J McCann; Steven R Goldberg
Journal:  Exp Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.157

Review 5.  Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?

Authors:  Pieter-Jan Carpentier; Frances R Levin
Journal:  Harv Rev Psychiatry       Date:  2017 Mar/Apr       Impact factor: 3.732

Review 6.  Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.

Authors:  Howard Schubiner
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  Treatment strategies for co-occurring ADHD and substance use disorders.

Authors:  John J Mariani; Frances R Levin
Journal:  Am J Addict       Date:  2007

Review 8.  Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.

Authors:  José Pérez de los Cobos; Núria Siñol; Víctor Pérez; Joan Trujols
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

9.  [Attention deficit hyperactivity disorder in adults. An overview].

Authors:  E Sobanski; B Alm
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

Review 10.  Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.

Authors:  Xavier Castells; Ruth Cunill; Dolors Capellà
Journal:  Eur J Clin Pharmacol       Date:  2012-09-16       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.